Mitiglinide calcium hydrate

• CAT Number: I002598
• CAS Number: 207844-01-7
• Molecular Formula: C19H25NO3 . 1/2 Ca . H2O
• Molecular Weight: 353.46
• Purity: ≥95%
• Target: KATP channel
• Solubility: 10 mM in DMSO
• Storage: Room Temperature
• IUPAC Name: calcium;(2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;dihydrate
• InChI: InChI=1S/2C19H25NO3.Ca.2H2O/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;;;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);;2*1H2/q;;+2;;/p-2/t2*15-,16+,17-;;;/m00.../s1
• InChIKey: QEVLNUAVAONTEW-UZYHXJQGSA-L
• SMILES: C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].O.O.[Ca+2]

Mitiglinide calcium hydrate（Cat No.:I002598） is a medication used in the treatment of type 2 diabetes. It functions as a highly selective antagonist of the ATP-sensitive potassium (KATP) channels. By blocking these channels, mitiglinide calcium hydrate stimulates insulin release from pancreatic beta cells, promoting glucose uptake and lowering blood sugar levels. This mechanism of action makes it particularly suitable for managing postprandial hyperglycemia, as it rapidly stimulates insulin secretion in response to meals. Mitiglinide calcium hydrate offers an effective therapeutic option for individuals with type 2 diabetes, helping to improve glycemic control and manage the condition.